Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019

BACKGROUND: Ceftolozane/tazobactam (C/T) is approved in 70 countries, including the United States, for the treatment of patients with hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible Gram-negative pathogens. C/T is of particular importance as an agent for the tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Karlowsky, James A., Lob, Sibylle H., Young, Katherine, Motyl, Mary R., Sahm, Daniel F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936229/
https://www.ncbi.nlm.nih.gov/pubmed/33676406
http://dx.doi.org/10.1186/s12866-021-02135-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936229/
https://www.ncbi.nlm.nih.gov/pubmed/33676406
http://dx.doi.org/10.1186/s12866-021-02135-z

Ejemplares similares